Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | Fe.S |
| Molecular Weight | 87.91 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[S--].[Fe++]
InChI
InChIKey=GNVXPFBEZCSHQZ-UHFFFAOYSA-N
InChI=1S/Fe.S/q+2;-2
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14116934http://www.foodchemadditives.com/products/Ferrous-Lactatehttp://nj.gov/health/eoh/rtkweb/documents/fs/0928.pdfDOI: 10.1021/ja00949a016 Retrived from http://pubs.acs.org/doi/abs/10.1021/ja00949a016https://www.drugs.com/inactive/ferrous-oxide-389.htmlhttp://www.druglead.com/cds/ferrous-iodide.htmlhttp://www.drugfuture.com/chemdata/ferroglycine-sulfate.htmlhttps://www.ncbi.nlm.nih.gov/pubmed/16694502
Curator's Comment: description was created based on several sources, including
http://www.minapharm.com/Public/ProductDetails.aspx?ProductCode=FERRO_SANO&langParam=en
Iron(II) gluconate (also known as a ferrous gluconate) is used in the treatment of hypochromic anemia. The real problem of iron therapy is not the theoretical utilization of iron, or the reticulocyte response, or even the daily increase of hemoglobin. These are important only as they indicate the return of the patients' blood to normal in a reasonably short time without undue inconvenience. Most patients suffering from hypochromic anemia respond well to most forms of iron when administered in adequate dosage. For the patients who cannot tolerate the usual iron compounds, it is important to have a medication which is effective and which causes minimum disturbance. Ferrous gluconate is such a medicament.
Originator
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Palliative | Unknown Approved UseUnknown |
|||
| Palliative | Unknown Approved UseUnknown |
|||
| Primary | Ferro Sanol Duodenal Approved UseFerro Sanol is an iron substitute in case of latent or manifest iron deficiency with and without development of anaemia. |
|||
PubMed
| Title | Date | PubMed |
|---|---|---|
| FERROUS IODIDE AS A SUBSTITUTE FOR VITAMIN A IN RATS. | 1932 Jul 1 |
|
| FERROUS IODIDE AND LINOLEIC ACID IN VITAMIN A DEFICIENCY. A REPLY TO CERTAIN CRITICISMS. | 1932 Nov 11 |
|
| THE ADMINISTRATION OF FERROUS IODIDE AND LINOLEIC ACID TO RATS DEPRIVED OF VITAMIN A. | 1932 Sep 30 |
|
| THE USE OF FERROUS GLUCONATE IN THE TREATMENT OF HYPOCHROMIC ANEMIA. | 1937 Jul |
|
| [Ferrous lactate as an oral iron preparation for therapeutic use]. | 1954 Nov 27 |
|
| Clinical appraisal of drugs with special reference to a new chelate hematinic. | 1957 Jul 11 |
|
| [FERROUS ASPARTATE IN THERAPY]. | 1964 Jan 1 |
|
| [Historical notes on the therapy of depression]. | 1986 Nov 22 |
|
| Determination of water in ferrous lactate by near infrared reflectance spectroscopy with a fibre-optic probe. | 1997 Oct |
|
| Decreased treatment failure rates following duodenal release ferrous glycine sulfate in iron deficiency anemia associated with autoimmune gastritis and Helicobacter pylori gastritis. | 2007 |
|
| Reversal of multidrug resistance by magnetic Fe3O4 nanoparticle copolymerizating daunorubicin and 5-bromotetrandrine in xenograft nude-mice. | 2009 |
|
| Bioleaching of heavy metals from sewage sludge by indigenous iron-oxidizing microorganisms using ammonium ferrous sulfate and ferrous sulfate as energy sources: a comparative study. | 2009 Nov 15 |
|
| The effect of iron treatment on adhesion molecules in patients with iron deficiency anemia. | 2010 Dec |
|
| Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. | 2011 Jun 10 |
|
| Tolerability of different oral iron supplements: a systematic review. | 2013 Apr |
|
| Effect of abomasal ferrous lactate infusion on phosphorus absorption in lactating dairy cows. | 2013 Jul |
|
| A practical and successful desensitization protocol for immediate hypersensitivity reactions to iron salts. | 2014 |
|
| Synthesis of phosphabenzenes by an iron-catalyzed [2+2+2] cycloaddition reaction of diynes with phosphaalkynes. | 2015 Jun 22 |
|
| Reactivity enhancement of iron sulfide nanoparticles stabilized by sodium alginate: Taking Cr (VI) removal as an example. | 2017 Jul 5 |
|
| Atomic Layer Deposition of Iron Sulfide and Its Application as a Catalyst in the Hydrogenation of Azobenzenes. | 2017 Mar 13 |
|
| Continuous sulfidogenic wastewater treatment with iron sulfide sludge oxidation and recycle. | 2017 May 1 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
215-268-6
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
DTXSID5061665
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
C022597
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
SUB23221
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
IRON(II) SULFIDE
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
1317-37-9
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
100000087151
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
75897
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
5803
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
TH5J4TUX6S
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
10290742
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | |||
|
m5355
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | Merck Index | ||
|
1724430
Created by
admin on Fri Dec 15 19:41:42 GMT 2023 , Edited by admin on Fri Dec 15 19:41:42 GMT 2023
|
PRIMARY | RxNorm |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD
